Aurobindo Pharma Gains 1.5% After FTC Clears Lannett Acquisition

Aurobindo Pharma shares rose 1.53% to ₹1,465.80 after the US Federal Trade Commission cleared its acquisition of Lannett Company LLC first announced in July 2025. Deal expected to close before end of June. Lannett gives Aurobindo a stronger foothold in four niche US generic drug markets including drugs preventing organ transplant rejection and treating dry mouth after radiation therapy. Limited competition in these segments means better pricing power and higher margins exactly what Indian pharma companies chase in the US market. Just five days ago Aurobindo's Telangana facility received an Official Action Indicated classification from the FDA a serious status requiring corrective action before the facility can resume US supplies. This remains an active headwind despite the Lannett good news. Aurobindo's simultaneous FTC approval and FDA concern taught me that pharma companies can face positive and negative regulatory developments at the same time, making it essential to track both acquisition progress and manufacturing compliance for stocks like Aurobindo, Cipla and Sun Pharma before investing. $AUROPHARMA $CIPLA $SUNPHARMA